Tracleer

 

Topic mentions per year

Topic mentions per year

2002-2017
02420022017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Bosentan (Tracleer) is an endothelin receptor antagonist prescribed for the treatment of pulmonary arterial hypertension (PAH… (More)
Is this relevant?
2013
2013
AIM To evaluate the efficiency and safety of long-term (12-month) treatment with the endothelin receptor antagonist bosentan… (More)
Is this relevant?
2012
2012
To the Editor: Liver toxicity is the most common reason for drug withdrawals (1). Drug-related hepatotoxicity is rare, however… (More)
  • figure 1
Is this relevant?
2011
Review
2011
Review
2011
We describe the case of a 37-year-old female with severe pulmonary hypertension on intravenous Remodulin and Tracleer who… (More)
Is this relevant?
Review
2008
Review
2008
Pulmonary arterial hypertension (PAH) is serious and a progressive disease with relatively poor prognosis if not identified and… (More)
Is this relevant?
Highly Cited
2007
Highly Cited
2007
The elimination process of the endothelin receptor antagonist bosentan (Tracleer) in humans is entirely dependent on metabolism… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Review
2005
Review
2005
In addition to its potent vasoconstricting effect, endothelin (ET)-1 induces proliferation of pulmonary vascular cells and… (More)
Is this relevant?
2004
2004
Since its discovery in 1988 by Yanagisawa et al., endothelin (ET), a potent vasoconstrictor, has been widely implicated in the… (More)
Is this relevant?